¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"crystal fibrin"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
¿µ¹® fibrin ÇÑ±Û ¼¶À¯¼Ò
¼³¸í   
  Çǰ¡ ±»À» ¶§ ¼¶À¯¼Ò¿¡ Æ®·ÒºóÀÌ ÀÛ¿ëÇÏ¿© »ý±â´Â ¼¶À¯ °°Àº ´Ü¹éÁú. ¹«»öÀ̳ª ¿¯Àº È²»öÀ» ¶í °íü·Î, ¹°¿¡ Àß ³ìÁö ¾ÊÀ¸¸ç Ç÷±¸¿Í ¾ûŰ¾î ÇǸ¦ ±»°Ô ÇÏ¿© ÃâÇ÷À» ±×Ä¡°Ô ÇÑ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • fibrin
    ¼¶À¯¼Ò, ÇǺ기
  • fibrin degradation product
    ¼¶À¯¼ÒºÐÇØ»ê¹°, ÇǺ기ºÐÇØ»ê¹°
  • fibrin stabilizing factor
    ¼¶À¯¼Ò¾ÈÁ¤ÀÎÀÚ
  • fibrin thrombus
    ¼¶À¯¼ÒÇ÷Àü, ÇǺ기Ç÷Àü
  • myogen fibrin
    ¹Ì¿À°Õ¼¶À¯¼Ò
  • biaxial crystal
    ½ÖÃà°áÁ¤
  • crystal
    1. °áÁ¤ 2. °áÁ¤Ã¼
  • crystal anisotropy
    °áÁ¤À̹æÇ⼺
  • crystal counter
    °áÁ¤°è¼ö±â
  • crystal deposition
    °áÁ¤Ä§Àü
  • crystal face
    °áÁ¤¸é
  • crystal optics
    °áÁ¤±¤ÇÐ
  • crystal rectifier
    °áÁ¤Á¤·ù±â
  • Charcot-Leyden crystal
    »þ¸£ÄÚ-¶óÀ̵§°áÁ¤
  • ear crystal
    ±Íµ¹, À̼®
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • fibrin
    ¼¶À¯¼Ò
  • crystal
    °áÁ¤
  • rock crystal
    ¼öÁ¤
  • urate crystal
    ¿ä»ê¿°°áÁ¤
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • fibrin
    ¼¶À¯¼Ò
  • fibrin thrombus
    ¼¶À¯¼ÒÇ÷Àü
  • fibrin degradation product
    ¼¶À¯¼ÒºÐÇØ»ê¹°
  • fibrin stabilizing factor
    ¼¶À¯¼Ò¾ÈÁ¤ÀÎÀÚ
  • myogen fibrin
    ¹Ì¿À°Õ¼¶À¯¼Ò
  • crystal anisotropy
    °áÁ¤À̹æÇ⼺
  • biaxial crystal
    ½ÖÃà°áÁ¤
  • crystal
    °áÁ¤
  • crystal counter
    °áÁ¤°è¼ö±â
  • crystal deposition
    °áÁ¤Ä§Àü
  • crystal face
    °áÁ¤¸é
  • crystal optics
    °áÁ¤±¤ÇÐ
  • crystal rectifier
    °áÁ¤Á¤·ù±â
  • ear crystal
    ±Íµ¹, À̼®
  • hemochromogen crystal
    Ç÷»ö¼Ò°áÁ¤
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Fibrin
    ¼¶À¯¼Ò(àéë«áÈ)
  • Fibrin-stabilizing factor
    ¼¶À¯¼Ò¾ÈÁ¤ÀÎÀÚ(¡­äÌïÒì×í­)
  • glomerulosclerosis,fibrin cap
    ¼¶À¯¼Òµ¤°³
  • gluten fibrin
    ±Û·çÅÙ¼¶À¯¼Ò.
  • Charcot-Leyden crystal
    »þ¸£ÄÚ- ¶óÀ̵§ °áÁ¤
  • acetylsulfadiazine crystal
    ¾Æ¼¼Æ¿¼³ÆÄµð¾ÆÁø°áÁ¤
  • acetylsulfamethoxazole crystal
    ¾Æ¼¼Æ¿¼³ÆÄ¸ÞÅå»çÁ¹°áÁ¤
  • acicular crystal
    ħ»ó°áÁ¤(öÜßÒÌ¿ïÜ).
  • ammonium biurate crystal
    ÀÌ¿ä»ê¾Ï¸ð´½°áÁ¤
  • ammonium magnesium phosphate crystal
    Àλê¾Ï¸ð´½¸¶±×³×½·°áÁ¤
  • ammonium urate crystal
    ¿ä»ê¾Ï¸ð´½°áÁ¤
  • hematin crystal
    Ç츶ƾ°áÁ¤
  • hemochromogen crystal
    Çì¸ðÅ©·Î¸ð°Õ°áÁ¤.
  • hemoglobin crystal
    Çì¸ð±Û·Îºó°áÁ¤, Ç÷»ö¼Ò°áÁ¤.
  • hydroxyapatite crystal
    ¼ö»êÈ­ÀÎȸ¼®°áÁ¤
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • crystal fibrin
    °áÁ¤¼¶À¯¼Ò, ¼öÁ¤Ã¼¼¶À¯¼Ò(¡­àéë«áÈ).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • carmine fibrin
    Ä«¸£¹Î¼¶À¯¼Ò(¡­àéë«áÈ).
  • fibrin
    ¼¶À¯¼Ò(àéë«áÈ), È­À̺기.
  • fibrin abnormality
    ¼¶À¯¼ÒÀÌ»ó
  • fibrin clot
    ¼¶À¯¼ÒÀÀ±«, ¼¶À¯¼ÒÀÀ°í
  • fibrin clot
    ¼¶À¯¼ÒÀÀ±«(¡­ëêÎÔ).
  • fibrin degradation product
  • fibrin degradation products =fDP
    ¼¶À¯¼ÒºÐÇØ»ê¹°
  • fibrin stabilizing factor
    ¼¶À¯¼Ò¾ÈÁ¤ÀÎÀÚ
  • fibrin stabilizing factor =FSF
    ¼¶À¯¼Ò¾ÈÁ¤ÀÎÀÚ(¡­äÌïÒì×í­), ¼¶À¯¼Ò¾ÈÁ¤ÀÎÀÚ.
  • fibrin-stabilizing factor
    ¼¶À¯¼Ò ¾ÈÁ¤ÀÎÀÚ, ¼¶À¯¼Ò¾ÈÁ¤ÀÎÀÚ.
  • glomerulosclerosis,fibrin cap
    ¼¶À¯¼Òµ¤°³
  • gluten fibrin
    ±Û·çÅÙ¼¶À¯¼Ò.
  • myogen fibrin
    ¹Ì¿À°ÕÈ­À̺기.
  • acetylsulfadiazine crystal
    ¾Æ¼¼Æ¿¼³ÆÄµð¾ÆÁø°áÁ¤
  • acetylsulfamethoxazole crystal
    ¾Æ¼¼Æ¿¼³ÆÄ¸ÞÅå»çÁ¹°áÁ¤
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Hydroxyapatite crystal
    ¼ö»êÈ­ÀÎȸ¼®°áÁ¤
    [¿¾ ¿ë¾î] ¼ö»êÈ­ÀÎȸ¼®°áÁ¤
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • fibrin
    ¼¶À¯¼Ò(àéë«áÈ)
  • fibrin monomer
    ¼¶À¯¼Ò ´Ü·®Ã¼(àéë«áÈÓ¤Õáô÷)
  • fibrin polymer
    ¼¶À¯¼Ò ÁßÇÕü(àéë«áÈñìùêô÷)
  • fibrin-stabilizing factor
    ¼¶À¯¼Ò ¾ÈÁ¤È­ÀÎÀÚ(àéë«áÈäÌïÒûùì×í­)
  • insoluble fibrin
    ºÒ¿ë¼º(ÝÕéÁàõ) È­À̺기
  • soluble fibrin
    "°¡¿ë(ʦéÁ)ÇǺ기, °¡¿ë ¼¶À¯¼Ò(ʦéÁàéë«áÈ)"
  • crystal
    °áÁ¤(Ì¿ïÜ)
  • crystal field splitting
    °áÁ¤ ÀåºÐÇÒ(Ì¿ïÜíÞÝÂùÜ)
  • crystal field theory
    °áÁ¤ Àå·Ð(Ì¿ïÜíÞÖå)
  • crystal lattice
    °áÁ¤ °ÝÀÚ(Ì¿ïÜÌ«í­)
  • crystal protein
    °áÁ¤ ´Ü¹éÁú(Ì¿ïÜÓ±ÛÜòõ)
  • liquid crystal
    ¾×Á¤(äûïÜ)
  • lyotropic liquid crystal
    À̾׾×Á¤(ìÆäûäûïÜ)
  • ribosome crystal
    ¶óÀ̺¸¼Ø °áÁ¤(Ì¿ïÜ)
  • rotating crystal method
    ȸÀü °áÁ¤¹ý(üÞï®Ì¿ïÜÛö)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • crystal
    °áÁ¤
  • crystal lattice
    °áÁ¤°ÝÀÚ
  • fibrin
    ¼¶À¯¼Ò, È­À̺기
  • fibrin plug
    È­À̺기ÀüÀÚ, ¼¶À¯¼ÒÀü
  • fibrin sealant
    ¼¶À¯¼Ò¹ÐÆóÁ¦(¹ÐºÀÁ¦)
  • piezoelectric crystal
    ¾ÐÀü°áÁ¤
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
SFC soluble fibrin complex; soluble fibrin-fibrinogen complex; spinal fluid count
CCF   1) Carotid(Carotico-) Cavernous Fistula
  2) Crystal-induced Chemotactic Fa...
CCF cancer coagulation factor; cardiolipin complement fixation; carotid-cavernous fistula; centrifuged c...
CCL carcinoma cell line; certified cell line; Charcot-Leyden crystal; continuing care level; critical ca...
CFSE crystal field stabilization energy
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
CLC Charcot-Leyden Crystal
CV Crystal Violet
LCD Liquid Crystal Display
LCT Liquid crystal thermography
MSU Monosodium urate crystal
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • crystal fibrin
    °áÁ¤ ¼¶À¯¼Ò, ¼öÁ¤Ã¼ ¼¶À¯¼Ò
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • fibrin bodies of pleura
    È丷 ¼¶À¯ ¼Òü
    È丷°­ ±âÀúºÎ±Ù¿¡ ÀÖ´Â °¡µ¿¼º ¶Ç´Â Á¡Âø¼º, ±¸»ó, µ¿Áú¼º, ±×¸®°í ÇѰ谡 ¸íÈ®ÇÑ À¯¹éü·Î¼­, È丷 »ïÃâ¾×, ±âÈä ¶Ç´Â Ç÷±âÈäÁõ¿¡¼­ ÀÌÂ÷ÀûÀ¸·Î ¹ß»ýÇÑ´Ù.
  • fibrin plug
    È­À̺기 ÀüÀÚ, ¼¶À¯¼ÒÀü
  • fibrin thrombus
    È­À̺êÁø Ç÷Àü
  • acetylsulfadiazine crystal
    ¾Æ¼¼Æ¿¼³ÆÄµð¾ÆÁø °áÁ¤
  • Charcot-Leyden crystal
    »þ¸£ÄÚ¶óÀ̵§ °áÁ¤
  • chromium-sensitized YAG crystal
    Å©·Ò °¨ÀÛ¼º YAG °áÁ¤
  • crystal cell
    °áÁ¤ ¼¼Æ÷
    ³»ºÎ¿¡ °¢Á¾ °áÁ¤À» ÇÔÀ¯ÇÏ´Â ¼¼Æ÷. ºÐºñ ¼¼Æ÷ÀÇ ÀÏÁ¾À¸·Î, º¸Åë ÁÖÀ§ÀÇ ¼¼Æ÷¿Í ¸ð¾çÀÌ ¾à°£ ´Ù¸£´Ù. Á¤¹æÁ¤°è ¶Ç´Â ´Ü»çÁ¤°è·Î µÈ Å« ¿Á»ì»ê Ä®½· °áÁ¤À» º£°í´Ï¾Æ¼Ó µî ½Ä¹°Á¶Á÷ ³»¿¡¼­ ÈçÈ÷ º¼ ¼ö ÀÖ´Ù. ¶§·Î´Â ¼ÒÇüÀÇ °áÁ¤ÀÌ ´Ù¼ö ±ºÁýÇÏ¿© °áÁ¤»ç°¡ µÇ°Å³ª ħ»ó °áÁ¤ÀÌ ´Ù¼ö ÆòÇàÀ¸·Î ¹è¿­µÇ¾î °áÁ¤ ¼ÓÀÌ µÈ´Ù
  • crystal chemistry
    °áÁ¤ È­ÇÐ
  • crystal lattice
    °áÁ¤ °ÝÀÚ
  • crystal system
    Á¤°è, °áÁ¤°è
  • ear crystal
    À̼®, ÆòÇü¼®
    µ¿ÀǾî=otolith.
  • enamel crystal
    ¹ý¶ûÁú °áÁ¤
  • fine crystal
    ¹Ì¼¼ °áÁ¤
  • hemoglobin crystal
    Çì¸ð±Û·Îºó °áÁ¤, Ç÷»ö¼Ò °áÁ¤
  • monosodium urate crystal
    ¿ä»ê ÀÏ ³ªÆ®·ý °áÁ¤
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
human fibrin foam A dry artificial sponge of human fibrin prepared by clotting with thrombin a foam of a solution of human fibrinogen; the clotted foam is dried from the frozen state and heated; used as a topical anticoagulant.
(05 Mar 2000)
fibrin <protein> The insoluble protein formed from fibrinogen by the proteolytic action of thrombin during normal clotting of blood. Fibrin forms the essential portion of the blood clot.
(12 Nov 1997)
fibrin calculus A urinary calculus formed largely from fibrinogen in blood.
(05 Mar 2000)
fibrin degradation products <haematology, investigation> A test that measures fibrin degradation products which result from the dissolution of a blood clot.
Normal value is less than 10 mcg/ml (micrograms per millilitre).
They may be increased in conditions such as burns, placental abruption, heart disease, DIC, after massive blood transfusion, hypoxia, intrauterine foetal death, portacaval shunt, leukaemia, transfusion reaction, transplant rejection, sepsis, renal failure and preeclampsia.
Acronym: FDP
(23 Sep 2002)
fibrin destabilase <enzyme> Hydrolyses the epsilon-(gamma-glutamyl)-lysine bonds of stabilised fibrin
Pharmacological action: fibrinolytic agents
Registry number: EC 3.4.99.-
Synonym: destabilase
(26 Jun 1999)
fibrin fibrinogen degradation products <chemical> Soluble protein fragments formed by the proteolytic action of plasmin on fibrin or fibrinogen. Fdp and their complexes profoundly impair the haemostatic process and are a major cause of haemorrhage in intravascular coagulation and fibrinolysis.
Pharmacological action: antithrombins.
(12 Dec 1998)
fibrin foam <chemical> A dry artificial sterile sponge of fibrin prepared by clotting with thrombin a foam or solution of fibrinogen. It is used in conjunction with thrombin as a haemostatic in surgery at sites where bleeding cannot be controlled by more common methods.
Pharmacological action: haemostatics, tissue adhesives.
(12 Dec 1998)
fibrinogen-fibrin conversion syndrome <syndrome> A syndrome characterised by hypofibrinogenaemia with incoagulable blood; it may be seen in abruptio placentae, prolonged retention of a dead foetus in an Rh-isosensitised mother, haemolytic blood reactions, bilateral renal cortical necrosis, and cases of trauma.
(05 Mar 2000)
fibrin-stabilizing factor <chemical> Fibrin stabilizing factor. It is a glycoprotein activated by thrombin in the presence of calcium to form factor xiiia. Factor xiii is found evenly distributed between plasma and platelets. Its function is to stabilise the formation of the fibrin polymer (clot) which culminates the coagulation cascade.
Chemical name: Blood-coagulation factor XIII
(12 Dec 1998)
fibrin thrombus A thrombus formed by repeated deposits of fibrin from the circulating blood; it usually does not completely occlude the vessel.
(05 Mar 2000)
fibrin tissue adhesive <chemical> An autologous or commercial tissue adhesive containing fibrinogen and thrombin. The commercial product is a two component system from human plasma that contains more than fibrinogen and thrombin. The first component contains highly concentrated fibrinogen, factor viii, fibronectin, and traces of other plasma proteins. The second component contains thrombin, calcium chloride, and antifibrinolytic agent such as aprotinin. Mixing of the two components promotes clotting and the formation and cross-linking of fibrin. The tissue adhesive is used for tissue sealing, haemostasis, and wound healing.
Pharmacological action: haemostatics, tissue adhesives.
(12 Dec 1998)
chiral crystal An enantiomorphic, dyssymmetric, optically active crystal.
(05 Mar 2000)
phase, crystal <microscopy> A specific crystal structure, usually given a name.
(05 Aug 1998)
clathrate crystal Lattice-like arrangement of molecules of one substance surrounding molecules of another substance.
(05 Mar 2000)
crystal A solid of regular shape and, for a given compound, characteristic angles, formed when an element or compound solidifies slowly enough, as a result either of freezing from the liquid form or of precipitating out of solution, to allow the individual molecules to take up regular positions with respect to one another.
Origin: G. Krystallos, clear ice, crystal
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • fibrin
    ¼¶À¯¼Ò
  • crystal
    ¼öÁ¤
  • Crystal Palace
    ¼öÁ¤±Ã(1851³â ·±´ø¿¡ ö°ñ°ú À¯¸®·Î ¸¸µé¾î ¼¼¿ü´ø ¿À¶ô°ü,1936³â ¼Ò½Ç)
  • crystal
    ¼öÁ¤;¼öÁ¤ Á¦Ç°(¼¼°ø);(Á¡Ä¡´Âµ¥ ¾²´Â)¼öÁ¤ ±¸½½;¼öÁ¤Á¡;ÄÆ±Û¶ó½º;°í±Þ ³³À¯¸®;Å©¸®½ºÅÐ(ÄÆ±Û¶ó½º)Á¦Ç°;ÄÆ±Û¶ó½º·Î ¸¸µç ½Ä±â·ù;(½Ã°èÀÇ)À¯¸® µ¤°³;°áÁ¤(ü);(°ËÆÄ¿ë)±¤¼®;¹ÝµµÃ¼;±¤¼® °ËÆÄ±â;±¤¼® Á¤·ù±â(¹ßÁø±â);¼öÁ¤(Áú.Á¦)ÀÇ;Å©¸®½ºÅÐ(ÄÆ±Û¶ó½º)Á¦ÀÇ;¼öÁ¤ °°Àº;¸¼°í Åõ¸í
  • crystal ball
    ¼öÁ¤(À¯¸®)±¸½½(Á¡Ä¡´Âµ¥ ¾¸);Á¡Ä¡´Â ¹æ¹ý(¼ö´Ü)
  • crystal clock
    ¼öÁ¤ ½Ã°è
  • crystal detector
    ±¤¼® °ËÆÄ±â
  • crystal gazer
    ¼öÁ¤ Á¡ÀïÀÌ
  • crystal gazing
    ¼öÁ¤Á¡(¼öÁ¤¾Ë¿¡ ³ªÅ¸³ª´Â ȯ»çÀ¸·Î Á¡À» ħ)
  • crystal glass
    =CRYSTAL
  • crystal laser
    °áÁ¤·¹ÀÌÀú
  • crystal lattice
    °áÁ¤ °ÝÀÚ
  • crystal pickup
    (ÀüÃà¿ë)Å©¸®½ºÅÐ ÇȾ÷ 0
  • crystal set
    ±¤¼® ¼ö½Å±â
  • crystal vision
    ¼öÁ¤Á¡(¿¡¼­ º¸À̴ ȯ»ó)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á